Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
N-methyl-1-(1,3-benzodioxol-5-yl)-2-buta (MBDB): its properties and possible risks
Autore:
Van Aerts, LAGJM; Mallaret, M; Rigter, H;
Indirizzi:
Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Utrecht, Netherlands Netherlands Inst Mental Hlth & Addict Utrecht Netherlands , Netherlands CHU Grenoble, Pharmacol Lab, F-38043 Grenoble, France CHU Grenoble Grenoble France F-38043 macol Lab, F-38043 Grenoble, France
Titolo Testata:
ADDICTION BIOLOGY
fascicolo: 3, volume: 5, anno: 2000,
pagine: 269 - 282
SICI:
1355-6215(200007)5:3<269:N(IPAP>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; AMPHETAMINE DERIVATIVES; ECSTASY MDMA; RAT-BRAIN; 3,4-METHYLENEDIOXYAMPHETAMINE MDA; THERAPEUTIC CLASS; RECREATIONAL USE; MEMORY DEFICITS; SEROTONIN; ANALOGS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
64
Recensione:
Indirizzi per estratti:
Indirizzo: Van Aerts, LAGJM Natl Inst Publ Hlth & Environm, Lab Med & Med Devices, POB 1, NL-3720 BA Bilthoven, Netherlands Natl Inst Publ Hlth & Environm POB 1Bilthoven Netherlands NL-3720 BA
Citazione:
L.A.G.J.M. Van Aerts et al., "N-methyl-1-(1,3-benzodioxol-5-yl)-2-buta (MBDB): its properties and possible risks", ADDICT BIOL, 5(3), 2000, pp. 269-282

Abstract

MBDB (N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane) is the alpha-ethyl homologue of MDMA (3,4-methylenedioxy-N-methylamphetamine). MBDB is metabolized and excreted similarly to MDMA: presumably, the majority of oral MBDB is excreted in urine unmetabolized. The main metabolic routes in man are thought to be O-dealkylation and subsequent methylation, sulphation and glucuronidation of the newly formed hydroxy groups. The major acute neuropharmacological effects of MBDB in the rat are an increase in serotonin release inthe brain and an inhibition of serotonin and noradrenaline re-uptake. These effects compare well with those of MDMA, although rite latter is more potent. MBDB may also slightly increase dopamine release and inhibit dopamine re-uptake, but to a lesser extent than MDMA. This is important, as dopaminerelease has been implicated ill the reinforcing qualities of substances such as cocaine and amphetamine. The neuroendocrine effects of MBDB resemble those of MDMA. Both substances increase plasma ACTH, corticosterone, prolactin and renin. The neurophysiological effects of MBDB are characterized by a decrease in electrical activity throughout the brain, most notably in thealpha(2) and delta frequency bands. In contrast, hallucinogens increase the activity in the alpha(1) band, especially in the corpus striatum. in drugdiscrimination tests in the rat, MBDB, like MDMA, can be distinguished clearly from both stimulants and hallucinogens. The class of substances to which MBDB belongs may be named entactogens. MBDB dose-dependently increases locomotor activity and decreases exploratory behaviour in the rat and causesdistress vocalization and wing extension in the newly hatched chicken. Therewarding properties of MBDB appear to be smaller than those of MDMA, as suggested by a 2.5 times weaker potency in the conditioned place preference test in rats. The main subjective effects of MBDB in man are a pleasant state of introspection, with greatly facilitated interpersonal communication and a pronounced sense of empathy and compassion between subjects. In this respect, MBDB again resembles MDMA. However, there are also differences. MBDB has a slower and more gentle onset of action than MDMA, produces less euphoria and has less stimulant properties. The few toxicological data available suggest that MBDB may cause serotonergic deficits in the brain, althoughthe potency of MBDB to cause this neurotoxic effect is smaller than that of MDMA. Severe acute reactions in man as have been reported far MDMA have not been published for MBDB. The dependence potential of MBDB appears to be small, probably even smaller than that of MDMA. MBDB has been available at least since 1994 but its position on the synthetic drugs market is marginal. Subjective reports indicate that MBDB is less popular among users than MDMA. The reason may be that MBDB produces less euphoria than MDMA. Another possible explanation is that MBDB largely lacks the stimulant properties of MDMA. We calculated a margin of safety with a method similar to one used inthe risk assessment of pharmaceuticals. The results suggest that MBDB is three times less likely to cause serotonergic brain deficits than MDMA. However, it should be noted that for bath substances the margin of safety is less than one, indicating that the risk of neurotoxicity is not negligible, In animals, serotonergic brain deficits after exposure to MDMA have been linked to the degeneration of serotonergic nerve terminals.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:28:14